Member Info for Krone

Good morning C79,

Pleased to hear all is well.

I concur with your comments regarding the disruptors!

I agree also that good news seems to be imminent.

Looking forward to your ongoing digging which helps to keep things fresh!

ATVB

Citizen79 - very much missing your posts, trust all is well.

Https://www.fiercebiotech.com/biotech/cymabay-board-pushed-50-cent-top-gileads-3250-share-offer

Https://investor.meipharma.com/node/11641/html

Someone here flagged Mei Pharma as potentially involved in SRA737 given the Nick Glover connection.

Filing in respect of $100m raise issued yesterday…

” We are a clinical-stage pharmaceutical company committed to developing novel and differentiated cancer therapies. We build our pipeline by acquiring promising cancer agents and creating value in programs through clinical development, strategic partnerships, and out-licensing or commercialization, as appropriate. Our approach to oncology drug development is to evaluate our drug candidates in combinations with standard-of-care therapies to overcome known resistance mechanisms and address clear medical needs to provide improved patient benefit. The drug candidate pipeline includes voruciclib, an oral cyclin-dependent kinase 9 ("CDK9") inhibitor, and ME-344, an intravenous small molecule mitochondrial inhibitor targeting the oxidative phosphorylation pathway. Our common stock is listed on the Nasdaq Capital Market under the symbol “MEIP.”

HBD - yes, probably is AI however much more enticing than anything Edison or Hybridan churn out!

Https://bnnbreaking.com/breaking-news/health/sareum-holdings-plcs-sdc-1801-a-new-era-in-psoriasis-treatment

Surprising that the characters allegedly managing the £70m CPF don’t consider the SRA737 licence newsworthy.

https://www.sixthelementcapital.com/news/

A Caesarean would simplify matters!

It’s an ill wind…. https://stocks.apple.com/ASgS7kgITTD-Pn0h9txwQ6g

Apols…this just came up on my twitter feed…again!

Https://x.com/edison_inv_res/status/1742576663190225271?s=46&t=_cUs6qcowyQbbF4MoPYSCw

Elcap - absolutely!

AZD-1775 (adavosertib), was discontinued by AstraZeneca, due to its low tolerability…..unlikely therefore that this paper furthers the aims of SRA737.

The comment at the October ‘23 IMC meeting was perhaps telling “ Our business model emphasises licensing our programmes at, OR EVEN BEFORE the early clinical stages.”

Https://www.fiercebiotech.com/biotech/biotech-dealmakers-its-everything-everywhere-all-once?

Disappointing in the context of the ‘we hear you’ response to the protestations re IR/PR at the AGM.

Https://medcitynews.com/2024/01/gsk-cancer-jpm-targeted-oncology-drugs/

Https://endpts.com/jpm24-merck-is-eyeing-new-immunology-deals-chief-medical-officer-says/

Https://www.biopharmadive.com/news/goldman-sachs-biotech-venture-fund-startups/703524/